Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses ROIV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ROIV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mayukh Sukhatme | $550,000 | $81,069,750 | $170,217,983 | — | — | — | $21,032 | $251,858,764 |
| President and Chief Investment Officer | ||||||||
| Matthew Gline | 725,000 | 4,978,875 | 157,577,851 | — | — | — | 12,018 | 163,293,744 |
| Chief Executive Officer | ||||||||
| Eric Venker | 600,208 | 6,038,175 | 2,203,200 | 2,933,103 | — | — | 32,736 | 11,807,422 |
| President and Immunovant CEO | ||||||||
| Rakhi Kumar | 370,156 | 1,650,328 | 412,382 | 1,862,828 | — | — | 398,244 | 4,693,938 |
| Former Chief Accounting Officer | ||||||||
| Richard Pulik | 437,750 | 1,113,674 | 410,061 | 2,163,910 | — | — | 1,755 | 4,127,151 |
| Chief Financial Officer | ||||||||
| Jennifer Humes | 41,897 | 281,450 | 1,231,437 | 826,878 | — | — | 1,293 | 2,382,956 |
| Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Mayukh Sukhatme | $251,858,764 | $574,560 | $48,925,582 | +251,284,204 |
| Matthew Gline | 163,293,744 | 738,189 | 48,978,825 | +162,555,555 |
| Eric Venker | 11,807,422 | 632,420 | 48,487,966 | +11,175,002 |
| Rakhi Kumar | 4,693,938 | 4,331,159 | — | +362,779 |
| Richard Pulik | 4,127,151 | 5,149,434 | — | −1,022,283 |
| Jennifer Humes | 2,382,956 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Eric Venker | President & Immunovant CEO | 2025-07-30 | A | 198,413 | $0 | $0 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-07-30 | A | 1,836,547 | 0 | 0 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-07-30 | A | 11,900,000 | 0 | 0 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-08-20 | D | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-08-20 | A | 100,000 | 4 | 385,000 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-08-20 | D | 1,235 | 12 | 14,474 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-08-20 | D | 7,051 | 12 | 82,638 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-08-20 | D | 100,000 | 12 | 1,172,000 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-08-28 | D | 2,340 | 12 | 27,940 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-09-03 | D | 194,933 | 13 | 2,518,534 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-09-03 | D | 385,816 | 13 | 5,000,175 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-09-03 | D | 1,195,000 | 13 | 14,937,500 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2025-09-10 | A | 14,524 | 0 | 0 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2025-09-10 | D | 5,270 | 14 | 72,568 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2025-09-10 | A | 33,726 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ilan Oren | Director | 2025-09-10 | A | 14,524 | 0 | 0 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2025-09-10 | D | 937 | 14 | 12,902 | Common | Form 4 ↗ |
| Keith Manchester | Director | 2025-09-10 | A | 14,524 | 0 | 0 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2025-09-10 | A | 14,524 | 0 | 0 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2025-09-10 | A | 33,726 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2025-09-10 | A | 33,726 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James C. Momtazee | Director | 2025-09-10 | D | 3,282 | 14 | 45,193 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2025-09-10 | A | 33,726 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2025-09-10 | A | 14,524 | 0 | 0 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2025-09-10 | D | 1,661 | 14 | 22,872 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2025-09-10 | D | 2,043 | 14 | 28,132 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2025-09-10 | A | 14,524 | 0 | 0 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2025-09-10 | A | 33,726 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith Manchester | Director | 2025-09-10 | A | 33,726 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-09-18 | A | 3,315 | 15 | 49,957 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | D | 611,000 | 15 | 9,061,130 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | D | 462,374 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | D | 683,818 | 15 | 10,223,079 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | D | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | A | 1,000,000 | 4 | 3,850,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | A | 462,374 | 4 | 1,780,140 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | D | 100,000 | 15 | 1,501,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | D | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | A | 100,000 | 4 | 385,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-09-19 | D | 316,182 | 15 | 4,739,568 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-09-20 | D | 2,129 | 15 | 32,020 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-09-28 | D | 2,341 | 15 | 35,513 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 128,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 107,131 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 180,859 | 4 | 696,307 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 24,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 128,295 | 7 | 955,798 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 171,396 | 16 | 2,800,611 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 24,900 | 7 | 185,505 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 67,171 | 16 | 1,064,660 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 10,307 | 16 | 163,366 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 127,355 | 16 | 2,018,577 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 127,355 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 10,307 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 180,859 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 67,171 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 19,141 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 138,602 | 16 | 2,245,352 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | D | 355,161 | 16 | 5,735,850 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 107,131 | 7 | 798,126 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-06 | A | 19,141 | 4 | 73,693 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-09 | D | 104,940 | 16 | 1,710,522 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-09 | D | 104,940 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-09 | A | 104,940 | 16 | 1,663,299 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-09 | D | 20,727 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-09 | A | 20,727 | 16 | 328,523 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-09 | D | 20,727 | 16 | 336,814 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | D | 318,282 | 17 | 5,426,708 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | A | 414,683 | 16 | 6,572,726 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | D | 414,683 | 17 | 7,020,583 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | D | 118,418 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | A | 118,418 | 16 | 1,876,925 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | D | 118,418 | 17 | 2,020,211 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | D | 318,282 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | A | 318,282 | 16 | 5,044,770 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-10-15 | D | 414,683 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ilan Oren | Director | 2025-10-20 | D | 281 | 18 | 4,985 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2025-10-20 | A | 1,507 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2025-10-20 | A | 789 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2025-10-20 | D | 158 | 18 | 2,803 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2025-10-20 | A | 1,056 | 0 | 0 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-11-07 | D | 200,000 | 20 | 4,044,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-11-07 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-11-07 | D | 200,000 | 20 | 4,044,000 | Derivative, Class A Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-11-13 | D | 539,650 | 21 | 11,068,222 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-11-13 | D | 287,283 | 21 | 5,978,359 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-11-13 | D | 1,027,670 | 20 | 20,892,531 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2025-11-19 | D | 150,000 | 20 | 3,030,000 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-11-19 | D | 850,000 | 20 | 17,212,500 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-11-19 | D | 175,000 | 20 | 3,542,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-11-19 | D | 150,000 | 20 | 3,030,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-11-19 | D | 150,000 | 20 | 3,030,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-11-19 | D | 125,000 | 20 | 2,520,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-11-19 | D | 125,000 | 20 | 2,520,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-11-19 | D | 850,000 | 20 | 17,212,500 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-11-19 | D | 850,000 | 20 | 17,212,500 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-11-19 | D | 175,000 | 20 | 3,542,000 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-11-19 | D | 125,000 | 20 | 2,520,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-11-19 | D | 175,000 | 20 | 3,542,000 | Common, indirect | Form 4 ↗ |
| Richard Pulik | CFO | 2025-11-20 | D | 1,235 | 20 | 25,033 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-11-20 | D | 7,051 | 20 | 142,924 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-09 | D | 200,000 | 21 | 4,170,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-09 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-09 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 832,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 1,975,858 | 22 | 43,389,842 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 353,745 | 22 | 7,800,077 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | A | 4,672,724 | 13 | 59,250,140 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | A | 832,453 | 13 | 10,555,504 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 478,708 | 22 | 10,555,511 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 1,095,550 | 22 | 23,707,702 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 2,696,866 | 22 | 59,223,177 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | A | 1,869,691 | 13 | 23,707,682 | Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 4,672,724 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 1,869,691 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vivek Ramaswamy | Greater-than-10% holder | 2025-12-11 | D | 774,142 | 22 | 16,752,433 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 234,096 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 566,116 | 22 | 12,273,395 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 3,739 | 22 | 81,062 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | A | 1,363,711 | 13 | 17,291,855 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 230,357 | 22 | 4,994,140 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 1,329,325 | 22 | 28,819,766 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | A | 234,096 | 4 | 950,430 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 2,272,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 943,527 | 22 | 20,455,665 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | A | 2,272,852 | 13 | 28,819,763 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 797,595 | 22 | 17,291,860 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2025-12-15 | D | 1,363,711 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| QVT Financial LP | — | 2025-12-16 | D | 642,282 | 23 | 14,823,869 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-12-16 | D | 432,718 | 23 | 9,974,150 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-12-16 | D | 155,076 | 23 | 3,569,850 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-12-16 | D | 275,000 | 23 | 6,305,750 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-12-16 | D | 189,538 | 23 | 4,391,595 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-12-16 | D | 642,282 | 23 | 14,823,869 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-12-16 | D | 642,282 | 23 | 14,823,869 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-12-16 | D | 189,538 | 23 | 4,391,595 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-12-16 | D | 275,000 | 23 | 6,305,750 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-12-16 | D | 155,076 | 23 | 3,569,850 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-12-16 | D | 189,538 | 23 | 4,391,595 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-12-16 | D | 432,718 | 23 | 9,974,150 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2025-12-16 | D | 155,076 | 23 | 3,569,850 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2025-12-16 | D | 275,000 | 23 | 6,305,750 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2025-12-16 | D | 432,718 | 23 | 9,974,150 | Common, indirect | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-17 | D | 26,831 | 23 | 619,528 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-17 | D | 59,513 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-17 | D | 32,682 | 23 | 754,627 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-17 | A | 59,513 | 13 | 754,625 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-12-20 | D | 2,129 | 22 | 47,711 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-23 | D | 313,841 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-23 | D | 117,848 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-12-23 | D | 146,731 | 22 | 3,285,307 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-23 | D | 200,000 | 22 | 4,490,000 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-12-23 | A | 175,380 | 22 | 3,937,281 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-12-23 | D | 260,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-23 | A | 313,841 | 4 | 1,208,288 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-12-23 | D | 110,489 | 0 | 0 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-12-23 | A | 260,000 | 4 | 1,001,000 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-12-23 | D | 260,000 | 22 | 5,837,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-23 | D | 75,000 | 23 | 1,689,750 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-12-23 | D | 64,891 | 22 | 1,458,101 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-23 | A | 117,848 | 4 | 453,715 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 2,449,877 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | A | 748,358 | 13 | 9,489,179 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 748,358 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 311,873 | 22 | 6,780,119 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | A | 2,449,877 | 13 | 31,064,440 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 436,485 | 22 | 9,489,184 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 1,018,995 | 22 | 22,122,381 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 1,430,882 | 22 | 31,064,448 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-01-12 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-01-12 | D | 200,000 | 22 | 4,384,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-01-12 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-01-20 | A | 1,164 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-01-20 | D | 122 | 23 | 2,804 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-01-20 | A | 815 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-01-20 | A | 609 | 0 | 0 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-01-20 | D | 124 | 23 | 2,850 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-01-20 | D | 54 | 23 | 1,241 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | A | 651,558 | 13 | 8,261,755 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | D | 312,117 | 26 | 8,261,737 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | D | 651,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | D | 339,441 | 26 | 8,985,003 | Common | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-11 | D | 150,000 | 27 | 4,008,000 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-11 | D | 150,784 | 26 | 3,994,268 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-11 | D | 225,000 | 27 | 5,962,500 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-11 | D | 275,000 | 27 | 7,359,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-11 | D | 150,784 | 26 | 3,994,268 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-11 | D | 275,000 | 27 | 7,359,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-11 | D | 150,784 | 26 | 3,994,268 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-11 | D | 425,000 | 27 | 11,334,750 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-11 | D | 425,000 | 27 | 11,334,750 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-11 | D | 225,000 | 27 | 5,962,500 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-11 | D | 150,000 | 27 | 4,008,000 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-11 | D | 225,000 | 27 | 5,962,500 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-11 | D | 150,000 | 27 | 4,008,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-11 | D | 275,000 | 27 | 7,359,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-11 | D | 425,000 | 27 | 11,334,750 | Common, indirect | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-02-13 | D | 200,000 | 26 | 5,298,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-02-13 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-02-13 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Rakhi Kumar | OPTION | 2024-04-22 | — | — | 230,548 | — | $1,862,828 |
| Eric Venker | RSU | 2024-07-26 | — | — | 204,000 | — | 2,203,200 |
| Richard Pulik | RSU | 2024-04-22 | — | — | 38,685 | — | 410,061 |
| Rakhi Kumar | RSU | 2024-04-22 | — | — | 38,685 | — | 412,382 |
| Eric Venker | OPTION | 2024-07-26 | — | — | 409,000 | — | 2,933,103 |
| Richard Pulik | OPTION | 2024-04-22 | — | — | 302,594 | — | 2,163,910 |
| Matthew Gline | RSU | 2024-07-26 | — | — | 2,754,821 | — | 29,752,067 |
| Mayukh Sukhatme | RSU | 2024-07-26 | — | — | 1,836,547 | — | 19,834,708 |
| Jennifer Humes | RSU | 2025-03-20 | — | — | 112,255 | — | 1,231,437 |
| Jennifer Humes | OPTION | 2025-03-20 | — | — | 115,108 | — | 826,878 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Rakhi Kumar | $412,382 | $0 | $1,862,828 | 0.0% |
| Eric Venker | 2,203,200 | 0 | 2,933,103 | 0.0% |
| Richard Pulik | 410,061 | 0 | 2,163,910 | 0.0% |
| Matthew Gline | 29,752,067 | 0 | 0 | 0.0% |
| Mayukh Sukhatme | 19,834,708 | 0 | 0 | 0.0% |
| Jennifer Humes | 1,231,437 | 0 | 826,878 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Rakhi Kumar | Option | 230,548 | 10.6 | — |
| Mayukh Sukhatme | Option | 82,065 | 10 | — |
| Eric Venker | Option | 58,616 | 10 | — |
| Matthew Gline | Option | 46,894 | 10 | — |
| Eric Venker | Option | 23,447 | 10 | — |
| Richard Pulik | Option | 39,177 | 6 | — |
| Mayukh Sukhatme | RSU | 1,836,547 | — | 18,530,759 |
| Jennifer Humes | Option | 115,108 | 10.97 | — |
| Eric Venker | Option | 4,475,029 | 3.85 | — |
| Matthew Gline | PSU | 2,125,595 | — | 21,447,254 |
| Eric Venker | RSU | 39,584 | — | 399,403 |
| Matthew Gline | Option | 4,475,029 | 3.85 | — |
| Rakhi Kumar | RSU | 3,750 | — | 37,838 |
| Matthew Gline | Option | 58,616 | 10 | — |
| Matthew Gline | RSU | 2,754,821 | — | 27,796,144 |
| Mayukh Sukhatme | PSU | 2,500,700 | — | 25,232,063 |
| Richard Pulik | RSU | 27,502 | — | 277,495 |
| Eric Venker | Option | 409,000 | 10.8 | — |
| Rakhi Kumar | Option | 3,566 | 10 | — |
| Richard Pulik | Option | 302,594 | 10.6 | — |
| Rakhi Kumar | Option | 149,171 | 8.8 | — |
| Eric Venker | RSU | 204,000 | — | 2,058,360 |
| Matthew Gline | RSU | 39,584 | — | 399,403 |
| Rakhi Kumar | Option | 270,833 | 3.85 | — |
| Richard Pulik | RSU | 38,685 | — | 390,332 |
| Richard Pulik | RSU | 33,352 | — | 336,522 |
| Richard Pulik | Option | 270,833 | 3.85 | — |
| Rakhi Kumar | RSU | 38,685 | — | 390,332 |
| Rakhi Kumar | RSU | 33,352 | — | 336,522 |
| Jennifer Humes | RSU | 112,255 | — | 1,132,653 |
| Richard Pulik | Option | 199,737 | 8.8 | — |
| Mayukh Sukhatme | Option | 1,097,325 | 10.96 | — |
| Mayukh Sukhatme | Option | 4,475,029 | 3.85 | — |
Our executive compensation program is designed to advance those objectives through a pay for performance philosophy and the alignment of the long-term interests of our NEOs with those of the Company's shareholders.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-09-10 | 316,651,402 | 203,244,184 | 64,550,276 | 60.91% | Passed |
| 2024 | 2024-09-10 | 540,184,951 | 64,461,892 | 587,930 | 89.34% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-09-10 | 60.91%a |
| 2024 | 2024-09-10 | 89.34%b |
a. Approved under the standard stated in the filing — “Abstentions, where applicable, are not considered to be votes cast and therefore will have no effect on the outcome of the vote for any such proposals as long as a quorum exists.”.
b. Approved under the standard stated in the filing — “Abstentions, where applicable, are not considered to be votes cast and therefore will have no effect on the outcome of the vote for any such proposals as long as a quorum exists proxy materials, or contact your broker, bank or other agent to request a proxy form.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 518 : 1 |
|---|---|
| CEO total compensation | $163,293,744 |
| Median employee compensation | $315,444 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ilan OrenIndependent · Board Chair · Compensation · Nominating/Governance (Chair) | $107,137 | $199,989 | $214,421 | $0 | $1 | $521,548 |
| Melissa EpperlyIndependent · Audit (Chair) | 75,000 | 199,989 | 214,421 | 0 | — | 489,410 |
| Daniel GoldIndependent · Compensation (Chair) | 70,000 | 199,989 | 214,421 | 0 | — | 484,410 |
| Meghan FitzGeraldIndependent · Audit · Nominating/Governance | 68,500 | 199,989 | 214,421 | 0 | — | 482,910 |
| Keith ManchesterIndependent · Audit | 62,250 | 199,989 | 214,421 | 0 | — | 476,660 |
| James C. MomtazeeIndependent · Nominating/Governance | 59,434 | 199,989 | 214,421 | 0 | — | 473,844 |
| Mayukh SukhatmeEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Matthew GlineEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $442,321 |
| Equity awards (grant-date value) | $1,199,934 |
| All other compensation | $1 |
| Total cost of the board | $1,642,256 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Roivant Sciences Ltd. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Roivant Sciences Ltd..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant Sciences Ltd. | 2024 | Matthew Gline | $725,000 | $157,577,851 | — | — | $163,293,744 |
| 2 | Exelixis, Inc. | 2025 | Michael Morrissey | 1,306,040 | 30,539,552 | 0 | 1,382,591 | 33,239,183 |
| 3 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 4 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 5 | Jazz Pharmaceuticals, Inc. | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 6 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 7 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 8 | Revolution Medicines, Inc. | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 9 | Vaxcyte, Inc. | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 10 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 11 | Neurocrine Biosciences Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 12 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 13 | Cerevel Therapeutics Holdings, Inc. | 2022 | N. Anthony Coles | 642,735 | 0 | 10,085,985 | 496,706 | 11,225,426 |
| 14 | Karuna Therapeutics, Inc. | 2022 | Steven Paul | 700,000 | 0 | 9,905,953 | 609,000 | 11,224,103 |
| 15 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 16 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 17 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 18 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 19 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 20 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 21 | CRISPR Therapeutics, Inc. | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 22 | Arcutis Biotherapeutics, Inc. | 2025 | Todd Franklin Watanabe | 713,333 | 2,067,190 | 3,848,958 | 579,584 | 7,223,065 |
| 23 | MoonLake Immunotherapeutics | 2025 | Jorge Santos da Silva | 762,386 | 4,000,021 | 0 | 0 | 4,943,209 |
| 24 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| — | Ascendis Pharma, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | ImmunoGen, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 94.5% | not disclosed | No | Aon |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| Amicus Therapeutics, Inc. | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | not disclosed | Yes — Total Shareholder Return (TSR) relative to NASDAQ Biotechnology Index | Pay Governance |
| Arcutis Biotherapeutics, Inc. | 125% | not disclosed | No | Pay Governance |
| Ascendis Pharma, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon (Human Capital Solutions practice, formerly Radford) |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Cerevel Therapeutics Holdings, Inc. | 128.8% | Options 100 | not disclosed | Pay Governance LLC |
| CRISPR Therapeutics, Inc. | 122.5% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| ImmunoGen, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Incyte Corporation | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Intra-Cellular Therapies, Inc. | 150% | RSU 75 · PSU 25 | Yes — Total Stockholder Return (TSR) relative to Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals, Inc. | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Jazz Pharmaceuticals, Inc. | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Karuna Therapeutics, Inc. | 145% | Options 100 | not disclosed | Aon plc (Human Capital Solutions practice) |
| MoonLake Immunotherapeutics | not disclosed | not disclosed | not disclosed | Deloitte |
| Neurocrine Biosciences Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Revolution Medicines, Inc. | 146% | Options 70 · RSU 30 | not disclosed | Compensia |
| Sarepta Therapeutics, Inc. | 100% | RSU 50 · PSU 50 | No | FW Cook |
| United Therapeutics Corporation | 221% | Options 50 · PSU 50 | No | Aon Human Capital Solutions |
| Vaxcyte, Inc. | 105% | not disclosed | not disclosed | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mayukh Sukhatme | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 251,858,764. Filing ↗machine: r7 · c24 · span 771923–771935 |
| 2 | Section 01, Matthew Gline | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 163,293,744. Filing ↗machine: r2 · c24 · span 751211–751223 |
| 3 | Section 01, Eric Venker | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 11,807,422. Filing ↗machine: r10 · c24 · span 784327–784338 |
| 4 | Section 01, Rakhi Kumar | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 4,693,938. Filing ↗machine: r14 · c24 · span 800174–800184 |
| 5 | Section 01, Richard Pulik | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 4,127,151. Filing ↗machine: r5 · c24 · span 763609–763619 |
| 6 | Section 01, Jennifer Humes | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 2,382,956. Filing ↗machine: r13 · c24 · span 795986–795996 |
| 7 | Section 03, Rakhi Kumar OPTION | DEF 14A | — | 0001140361-25-027846 | Section “Grants of Plan-Based Awards for Fiscal 2024” · grants of plan-based awards table. Filing ↗ |
| 8 | Section 03, Eric Venker RSU | DEF 14A | — | 0001140361-25-027846 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t133 · r3 · c9 · span 463991–463998 |
| 9 | Section 03, Richard Pulik RSU | DEF 14A | — | 0001140361-25-027846 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Rakhi Kumar RSU | DEF 14A | — | 0001140361-25-027846 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗ |
| 11 | Section 03, Eric Venker OPTION | DEF 14A | — | 0001140361-25-027846 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t133 · r3 · c12 · span 464497–464504 |
| 12 | Section 03, Richard Pulik OPTION | DEF 14A | — | 0001140361-25-027846 | Section “Grants of Plan-Based Awards for Fiscal 2024” · grants of plan-based awards table. Filing ↗ |
| 13 | Section 03, Matthew Gline RSU | DEF 14A | — | 0001140361-25-027846 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t133 · r1 · c9 · span 459048–459057 |
| 14 | Section 03, Mayukh Sukhatme RSU | DEF 14A | — | 0001140361-25-027846 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t133 · r2 · c9 · span 461515–461524 |
| 15 | Section 03, Jennifer Humes RSU | DEF 14A | — | 0001140361-25-027846 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗ |
| 16 | Section 03, Jennifer Humes OPTION | DEF 14A | — | 0001140361-25-027846 | Section “Grants of Plan-Based Awards for Fiscal 2024” · grants of plan-based awards table. Filing ↗ |
| 17 | Section 07, pay ratio | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “CEO Pay Ratio”. As printed: 518 : 1. Filing ↗ |
| 18 | Section 08, Ilan Oren | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 521,548. Filing ↗machine: t63 · r4 · c15 · span 253114–253122 |
| 19 | Section 08, Melissa Epperly | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 489,410. Filing ↗machine: t63 · r6 · c15 · span 258986–258994 |
| 20 | Section 08, Daniel Gold | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 484,410. Filing ↗machine: t63 · r2 · c15 · span 247286–247294 |
| 21 | Section 08, Meghan FitzGerald | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 482,910. Filing ↗machine: t63 · r7 · c15 · span 261565–261573 |
| 22 | Section 08, Keith Manchester | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 476,660. Filing ↗machine: t63 · r3 · c15 · span 250007–250015 |
| 23 | Section 08, James C. Momtazee | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 473,844. Filing ↗machine: t63 · r5 · c15 · span 255833–255841 |
| 24 | Section 08, Mayukh Sukhatme | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 08, Matthew Gline | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 02, Eric Venker 2025-07-30 | Form 4 | 2025-08-01 | 0001140361-25-028452 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Frank Torti 2025-07-30 | Form 4 | 2025-08-01 | 0001140361-25-028453 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Frank Torti 2025-07-30 | Form 4 | 2025-08-01 | 0001140361-25-028453 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Eric Venker 2025-08-20 | Form 4 | 2025-08-22 | 0001140361-25-032404 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Eric Venker 2025-08-20 | Form 4 | 2025-08-22 | 0001140361-25-032404 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Richard Pulik 2025-08-20 | Form 4 | 2025-08-22 | 0001140361-25-032405 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Eric Venker 2025-08-20 | Form 4 | 2025-08-22 | 0001140361-25-032404 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Eric Venker 2025-08-20 | Form 4 | 2025-08-22 | 0001140361-25-032404 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Richard Pulik 2025-08-28 | Form 4 | 2025-09-02 | 0001140361-25-033687 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Vivek Ramaswamy 2025-09-03 | Form 4 | 2025-09-05 | 0002007997-25-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Vivek Ramaswamy 2025-09-03 | Form 4 | 2025-09-05 | 0002007997-25-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Vivek Ramaswamy 2025-09-03 | Form 4 | 2025-09-05 | 0002007997-25-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Daniel Gold 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Daniel Gold 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Daniel Gold 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Ilan Oren 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Meghan FitzGerald 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Keith Manchester 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034934 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Meghan FitzGerald 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Meghan FitzGerald 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Epperly Melissa B, 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, James C. Momtazee 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, James C. Momtazee 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Epperly Melissa B, 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Epperly Melissa B, 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Ilan Oren 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, James C. Momtazee 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Ilan Oren 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Keith Manchester 2025-09-10 | Form 4 | 2025-09-12 | 0001140361-25-034934 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Matthew Gline 2025-09-18 | Form 4 | 2025-09-18 | 0001140361-25-035435 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Eric Venker 2025-09-19 | Form 4 | 2025-09-23 | 0001140361-25-035890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Richard Pulik 2025-09-20 | Form 4 | 2025-09-23 | 0001140361-25-035891 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Richard Pulik 2025-09-28 | Form 4 | 2025-09-30 | 0001140361-25-036831 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Eric Venker 2025-10-06 | Form 4 | 2025-10-08 | 0001140361-25-037740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Eric Venker 2025-10-09 | Form 4 | 2025-10-14 | 0001140361-25-038126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Eric Venker 2025-10-09 | Form 4 | 2025-10-14 | 0001140361-25-038126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Eric Venker 2025-10-09 | Form 4 | 2025-10-14 | 0001140361-25-038126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Eric Venker 2025-10-09 | Form 4 | 2025-10-14 | 0001140361-25-038126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Eric Venker 2025-10-09 | Form 4 | 2025-10-14 | 0001140361-25-038126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Eric Venker 2025-10-09 | Form 4 | 2025-10-14 | 0001140361-25-038126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Eric Venker 2025-10-15 | Form 4 | 2025-10-17 | 0001140361-25-038545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Ilan Oren 2025-10-20 | Form 4 | 2025-10-22 | 0001140361-25-038995 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Ilan Oren 2025-10-20 | Form 4 | 2025-10-22 | 0001140361-25-038995 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, James C. Momtazee 2025-10-20 | Form 4 | 2025-10-22 | 0001140361-25-038996 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, James C. Momtazee 2025-10-20 | Form 4 | 2025-10-22 | 0001140361-25-038996 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Epperly Melissa B, 2025-10-20 | Form 4 | 2025-10-22 | 0001140361-25-038997 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Eric Venker 2025-11-07 | Form 4 | 2025-11-07 | 0001140361-25-041214 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Eric Venker 2025-11-07 | Form 4 | 2025-11-07 | 0001140361-25-041214 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Eric Venker 2025-11-07 | Form 4 | 2025-11-07 | 0001140361-25-041214 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Vivek Ramaswamy 2025-11-13 | Form 4 | 2025-11-17 | 0001635075-25-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Vivek Ramaswamy 2025-11-13 | Form 4 | 2025-11-17 | 0001635075-25-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Vivek Ramaswamy 2025-11-13 | Form 4 | 2025-11-17 | 0001635075-25-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Daniel Gold 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291731 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Daniel Gold 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291731 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, QVT Financial LP 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291727 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Keith Manchester 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, QVT Financial LP 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291727 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, QVT Financial LP 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291727 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Keith Manchester 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Keith Manchester 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, QVT Financial LP 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291727 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Daniel Gold 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291731 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Daniel Gold 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291731 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Keith Manchester 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Richard Pulik 2025-11-20 | Form 4 | 2025-11-24 | 0001140361-25-043203 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Eric Venker 2025-11-20 | Form 4 | 2025-11-24 | 0001140361-25-043201 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Eric Venker 2025-12-09 | Form 4 | 2025-12-11 | 0001140361-25-045279 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Eric Venker 2025-12-09 | Form 4 | 2025-12-11 | 0001140361-25-045279 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Eric Venker 2025-12-09 | Form 4 | 2025-12-11 | 0001140361-25-045279 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Vivek Ramaswamy 2025-12-11 | Form 4 | 2025-12-15 | 0001635075-25-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Matthew Gline 2025-12-15 | Form 4 | 2025-12-17 | 0001140361-25-045906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, QVT Financial LP 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325343 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Daniel Gold 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325359 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Daniel Gold 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325359 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, QVT Financial LP 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325343 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, QVT Financial LP 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325343 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Daniel Gold 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325359 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Keith Manchester 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325355 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Daniel Gold 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325359 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Keith Manchester 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325355 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Keith Manchester 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325355 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Keith Manchester 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325355 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, QVT Financial LP 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325343 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, QVT Financial LP 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325343 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Daniel Gold 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325359 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Keith Manchester 2025-12-16 | Form 4 | 2025-12-18 | 0001193125-25-325355 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Mayukh Sukhatme 2025-12-17 | Form 4 | 2025-12-19 | 0001140361-25-046247 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Mayukh Sukhatme 2025-12-17 | Form 4 | 2025-12-19 | 0001140361-25-046247 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Mayukh Sukhatme 2025-12-17 | Form 4 | 2025-12-19 | 0001140361-25-046247 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Mayukh Sukhatme 2025-12-17 | Form 4 | 2025-12-19 | 0001140361-25-046247 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Richard Pulik 2025-12-20 | Form 4 | 2025-12-23 | 0001140361-25-046601 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Eric Venker 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Eric Venker 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Richard Pulik 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Eric Venker 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Frank Torti 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046788 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Richard Pulik 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Eric Venker 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Frank Torti 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046788 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Richard Pulik 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Richard Pulik 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Eric Venker 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Frank Torti 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046788 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Eric Venker 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Eric Venker 2026-01-12 | Form 4 | 2026-01-14 | 0001140361-26-001239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Eric Venker 2026-01-12 | Form 4 | 2026-01-14 | 0001140361-26-001239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Eric Venker 2026-01-12 | Form 4 | 2026-01-14 | 0001140361-26-001239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Ilan Oren 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, James C. Momtazee 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Epperly Melissa B, 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, James C. Momtazee 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Ilan Oren 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Epperly Melissa B, 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Keith Manchester 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Daniel Gold 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Keith Manchester 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Keith Manchester 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, QVT Financial LP 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Daniel Gold 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Keith Manchester 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Keith Manchester 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Daniel Gold 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, QVT Financial LP 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Daniel Gold 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Daniel Gold 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, QVT Financial LP 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 02, QVT Financial LP 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 222 | Section 02, QVT Financial LP 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 223 | Section 02, Eric Venker 2026-02-13 | Form 4 | 2026-02-18 | 0001635088-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 224 | Section 02, Eric Venker 2026-02-13 | Form 4 | 2026-02-18 | 0001635088-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 225 | Section 02, Eric Venker 2026-02-13 | Form 4 | 2026-02-18 | 0001635088-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 226 | Section 06, 2025 vote | Form 8-K | 2025-09-11 | 0001140361-25-034711 | Item 5.07 · say-on-pay result. As reported: 60.91% (votes for as printed: 316,651,402). Filing ↗ |
| 227 | Section 06, 2024 vote | Form 8-K | 2024-09-16 | 0001140361-24-041188 | Item 5.07 · say-on-pay result. As reported: 89.34% (votes for as printed: 540,184,951). Filing ↗ |
| 228 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 229 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 230 | Section 09b board cost (computed) | Computed | — | computed | Cash 442,321 + equity 1,199,934 + all other 1 = 1,642,256, summed across the director compensation table rows.machine: formula: Σ = 1,642,256 |
| 231 | Roivant Sciences Ltd. (subject), Section 10b CEO total | DEF 14A | 2025-07-29 | 0001140361-25-027846 | CEO total compensation as printed in Roivant Sciences Ltd.'s own proxy. As printed: 163,293,744. Filing ↗machine: r2 · c24 · span 751211–751223 |
| 232 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 233 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 234 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 235 | Jazz Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals, Inc.'s own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 236 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 237 | BridgeBio Pharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 238 | Revolution Medicines, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182453 | CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618 |
| 239 | Vaxcyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173672 | CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207 |
| 240 | Blueprint Medicines Corporation, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: t150 · r5 · c14 · span 1101152–1101162 |
| 241 | Neurocrine Biosciences Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 242 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 243 | Cerevel Therapeutics Holdings, Inc., Section 10b CEO total | DEF 14A | 2023-04-28 | 0000950170-23-015766 | CEO total compensation as printed in Cerevel Therapeutics Holdings, Inc.'s own proxy. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016 |
| 244 | Karuna Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2023-04-27 | 0000950170-23-014979 | CEO total compensation as printed in Karuna Therapeutics, Inc.'s own proxy. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694 |
| 245 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 246 | Axsome Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 247 | Intra-Cellular Therapies, Inc., Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 248 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 249 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 250 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 251 | CRISPR Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-165158 | CEO total compensation as printed in CRISPR Therapeutics, Inc.'s own proxy. As printed: 7,678,477. Filing ↗machine: t21 · r2 · c26 · span 821649–821658 |
| 252 | Arcutis Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001787306-26-000028 | CEO total compensation as printed in Arcutis Biotherapeutics, Inc.'s own proxy. As printed: 7,223,065. Filing ↗machine: r2 · c42 · span 646815–646824 |
| 253 | MoonLake Immunotherapeutics, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001140361-26-015916 | CEO total compensation as printed in MoonLake Immunotherapeutics's own proxy. As printed: 4,943,209. Filing ↗machine: t83 · r2 · c24 · span 431198–431207 |
| 254 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 255 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 256 | Section 10a, Jazz Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 257 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 258 | Section 10a, CRISPR Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-165158 | CRISPR Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 259 | Section 10a, Karuna Therapeutics, Inc. reciprocity | DEF 14A | — | 0000950170-23-014979 | Karuna Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 260 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 261 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 262 | Section 10a, MoonLake Immunotherapeutics reciprocity | DEF 14A | — | 0001140361-26-015916 | MoonLake Immunotherapeutics's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 263 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 264 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 265 | Section 10a, Neurocrine Biosciences Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 266 | Section 10a, Arcutis Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0001787306-26-000028 | Arcutis Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 267 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 268 | Section 10a, Revolution Medicines, Inc. reciprocity | DEF 14A | — | 0001193125-26-182453 | Revolution Medicines, Inc. names Roivant Sciences Ltd. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 269 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 270 | Section 10a, Axsome Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 271 | Section 10a, Blueprint Medicines Corporation reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines Corporation's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 272 | Section 10a, Intra-Cellular Therapies, Inc. reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 273 | Section 10a, Vaxcyte, Inc. reciprocity | DEF 14A | — | 0001193125-26-173672 | Vaxcyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 274 | Section 10a, BridgeBio Pharma, Inc. reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma, Inc. names Roivant Sciences Ltd. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 275 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 276 | Section 10a, Cerevel Therapeutics Holdings, Inc. reciprocity | DEF 14A | — | 0000950170-23-015766 | Cerevel Therapeutics Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |